Skip to main content
Retour
Watch Compare

CNBX Pharmaceuticals Inc.

Qualité des données : 100%
CNBX
OTC Manufacturing Chemicals
0,00 €
0,00 € (0,00%)
Cap. Boursière: 87 076,0
Prix
0,00 €
Cap. Boursière
87 076,0
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -179 636,0

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,00
Interest Coverage-3,60

Valorisation

PE (TTM)
-0,22
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E -0,2 -1,5
P/B — 1,6
ROE % — -53,6
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -393 343,0
ROE N/A ROA -2641,92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -179 636,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,00
Interest Coverage -3,60 Asset Turnover 0,00
Working Capital -2,57 M Tangible Book Value -2,57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,22 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -206,30%
Market Cap 87 076,0 Enterprise Value 79 373,0
Per Share
EPS (Diluted TTM) 0,00 Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45,67%
SBC-Adj. FCF -214 611 Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 130 074,0 410 165,0 — 0,0
Net Income -313 976,0 -695 198,0 -3,71 M -3,72 M -3,19 M
EPS (Diluted) 0,00 -0,02 -0,42 -3,59 —
Gross Profit — — — — —
Operating Income -271 691,0 -583 139,0 -931 380,0 -2,95 M -2,60 M
EBITDA — — — — —
R&D Expenses 0,0 194 788,0 431 565,0 1,18 M 1,77 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 39 819,0 — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18 437,0 31 383,0 499 039,0 811 166,0 3,08 M
Total Liabilities — — — — —
Shareholders' Equity -2,50 M -2,48 M -2,02 M -1,63 M 1,81 M
Total Debt — — — — —
Cash & Equivalents 15 111,0 26 416,0 129 696,0 117 515,0 1,39 M
Current Assets 18 437,0 31 383,0 224 308,0 198 287,0 1,59 M
Current Liabilities 2,51 M 2,51 M 2,52 M 2,44 M 1,27 M